Article Text

Download PDFPDF
Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q What are the effects of adjuvant chemotherapy, tamoxifen, and ovarian ablation or suppression on recurrence and survival 15 years after diagnosis of early breast cancer?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Oncology ★★★★★★☆


Embedded ImageData sources:

Medline, published lists of randomised trials, hand searching selected journals, meeting abstracts, references of published trials and reviews, and contacting experts repeatedly over a 15 year period.

Embedded ImageStudy selection and assessment:

unconfounded randomised controlled trials (RCTs) of adjuvant systemic therapies for early breast cancer begun before 1995. Individual patient data and updated follow up were sought on every woman included in the studies. Analyses were by intention to treat.

Embedded ImageOutcomes:

main outcomes were death from breast cancer, death from other causes, breast cancer recurrence, and incidence of second cases of cancers. …

View Full Text


  • For correspondence: EBCTCG Secretariat, CTSU, Radcliffe Infirmary, Oxford, UK. bc.overview{at}

  • Source of funding: UK Medical Research Council.